In a randomized, double-blind study of 22 patients with mild to severe UC, SOR102 was found to be safe and well-tolerated. Most adverse events were mild to moderate, with no significant differences in safety compared to the placebo group.
By working directly in the GI tissue, it may achieve higher local concentrations than systemic drugs without increasing the risk of body-wide infections.
is an investigational, orally delivered biologic currently in clinical development for the treatment of inflammatory bowel disease (IBD), specifically ulcerative colitis (UC) . Developed by Sorriso Pharmaceuticals, it represents a potential paradigm shift in how advanced therapies are administered to patients with chronic gastrointestinal inflammation. What is SOR102?
Recent studies suggest that blocking both TNF and IL-23 is more effective than blocking either one alone. SOR102 does this within a single molecule. Future Outlook
: